Intent-to-treat analysis | (n = 26) |
  4-week point prevalence | 23.1% |
  24-week point-prevalence | 15.4% |
  4-week continuous | 15.4% |
  24-week continuous | 7.7% |
Completer analysis | (n = 20) |
  4-week point prevalence | 30.0% |
  24-week point-prevalence | 20.0% |
  4-week continuous | 20.0% |
  24-week continuous | 10.0% |